Table 5.
Recurrence rates of HZ (per 100 persons - year), overall and by age groups and IC condition
| IC condition | Recurrence rate of HZ per 100 PY (95% CI) | |||||||
|---|---|---|---|---|---|---|---|---|
| 18–29 | 30–39 | 40–49 | 50–59 | 60–69 | 70–79 | ≥ 80 | Overall | |
| Population | 0.99 (0.9–1.09) | 1.13 (1.05–1.21) | 1.19 (1.11–1.27) | 1.31 (1.25–1.38) | 1.7 (1.63–1.77) | 2.2 (2.12–2.28) | 2.71 (2.6–2.83) | 1.66 (1.63–1.69) |
| IC-free cohort | 0.93 (0.84–1.02) | 1.08 (1–1.16) | 1.1 (1.02–1.18) | 1.23 (1.16–1.3) | 1.62 (1.55–1.7) | 2.09 (2–2.18) | 2.62 (2.49–2.75) | 1.56 (1.53–1.59) |
| IC cohort | 1.88 (1.44–2.42) | 1.63 (1.32–1.99) | 1.87 (1.6–2.18) | 1.81 (1.61–2.03) | 2.08 (1.9–2.27) | 2.69 (2.48–2.92) | 3.13 (2.84–3.44) | 2.28 (2.18–2.38) |
| HSCT | 7.38 (1.52–21.56) | 2.33 (0.28–8.4) | 5.05 (2.18–9.95) | 5.39 (2.87–9.22) | 5.48 (3.07–9.04) | 13.84 (4.49–32.31) | 5.5 (4.03–7.34) | |
| SOT | 2.83 (0.58–8.26) | 2.87 (1.15–5.92) | 3.12 (1.7–5.23) | 2.94 (1.94–4.28) | 2.62 (1.8–3.68) | 3.55 (2.38–5.1) | 3.27 (1.74–5.59) | 3.01 (2.5–3.58) |
| HN | 3.32 (1.93–5.31) | 1.89 (1.01–3.23) | 2.04 (1.21–3.23) | 3.27 (2.45–4.27) | 3.08 (2.42–3.85) | 4.16 (3.39–5.04) | 4.03 (3.08–5.18) | 3.35 (3.01–3.73) |
| SON | 1.88 (0.39–5.5) | 2.32 (1.27–3.89) | 1.82 (1.23–2.58) | 1.82 (1.49–2.2) | 2.04 (1.78–2.33) | 2.46 (2.19–2.75) | 3.18 (2.81–3.58) | 2.37 (2.22–2.53) |
| NEOPLASIAS | 2.93 (1.79–4.52) | 1.99 (1.3–2.91) | 1.91 (1.41–2.52) | 2 (1.69–2.36) | 2.17 (1.92–2.43) | 2.67 (2.42–2.95) | 3.24 (2.89–3.62) | 2.5 (2.36–2.64) |
| HIV | 3.53 (1.3–7.69) | 1.99 (1.11–3.28) | 3.01 (2.22–3.99) | 3.96 (2.61–5.76) | 4.76 (2.38–8.52) | 8.39 (2.73–19.59) | 0 (0–48.47) | 3.2 (2.63–3.85) |
| AUTOIMMUNE | 1.65 (1.19–2.24) | 1.48 (1.13–1.9) | 1.66 (1.33–2.05) | 1.62 (1.37–1.91) | 2.1 (1.84–2.4) | 2.84 (2.5–3.21) | 3.1 (2.6–3.66) | 2.12 (1.98–2.26) |
| RA | 1.57 (0.19–5.67) | 1.49 (0.48–3.47) | 2.06 (1.18–3.35) | 1.68 (1.12–2.43) | 2.58 (2–3.28) | 2.6 (1.99–3.34) | 3.33 (2.42–4.48) | 2.43 (2.12–2.77) |
| SLE | 0 (0–5.28) | 2.73 (0.89–6.37) | 3.21 (1.39–6.33) | 2.97 (1.42–5.46) | 3.23 (1.48–6.13) | 1.3 (0.16–4.69) | 4.01 (0.83–11.71) | 2.75 (1.93–3.79) |
| IBD | 1.95 (0.71–4.24) | 2.19 (1.16–3.74) | 1.58 (0.82–2.77) | 1.65 (0.94–2.68) | 2.5 (1.64–3.63) | 3.49 (2.3–5.07) | 4.73 (2.97–7.16) | 2.48 (2.06–2.96) |
| PSORIASIS | 1.64 (1.06–2.42) | 1.36 (0.9–1.96) | 1.28 (0.85–1.85) | 1.46 (1.1–1.9) | 1.71 (1.34–2.16) | 2.39 (1.89–2.98) | 2.88 (2.04–3.96) | 1.77 (1.58–1.97) |
| MS | 0 (0–9.86) | 1.59 (0.19–5.73) | 4.08 (1.5–8.87) | 0 (0–2.08) | 2.59 (0.71–6.64) | 2.89 (0.35–10.44) | 0 (0–37.33) | 1.94 (1.06–3.26) |
| AT | 0 (0–9.6) | 2.34 (0.28–8.45) | 0.57 (0.01–3.16) | 1.75 (0.71–3.61) | 1.8 (0.66–3.92) | 2.5 (0.81–5.84) | 2.97 (0.61–8.69) | 1.8 (1.15–2.68) |
CI Confidence interval, IC immunocompromised, HSCT haematopoietic stem cell transplant, SOT solid organ transplantation, HN haematological neoplasia, SON solid organ neoplasia, NEOPLASIAS neoplasias overall, HIV human immunodeficiency virus, AUTOIMMUNE RA rheumatoid arthritis, SLE systemic lupus erythematosus, IBD Inflammatory bowel disease, MS multiple sclerosis, AT autoimmune thyroiditis, AUTOIMMUNE immunodeficiency disorders and autoimmune diseases overall (See supplementary Table 1)